Professor Iain McInnes Reviews the Most Notable Papers from 2018

Please click the links below to go to the CSF review of each paper

2018 brought a wealth of new data in cytokine signalling and IL-6 that helps inform current clinical practice and brings the promise of new options in the future. There was good data on the use of sub cutaneous tocilizumab as well as strategies in early RA and for methotrexate tapering. For the currently marketed JAK inhibitors, tofacitinib and baricitinib, continuous long-term efficacy and safety data further support its current use and applications. On the development side, the outcomes of the phase 3 upadacitinib SELECT program give cause for optimism in the treatment of moderate-to-severe RA, while filgotinib achieved its primary endpoint in the FINCH2 study, we look forward to seeing additional results soon. With all this new data, our Steering Committee Chair, Professor McInnes, has selected some of the most notable and influential papers reviewed on the CSF this year. You can see some of his selections by clicking the links below, to view the full list, please view the slides: Lipid profile and effect of statin treatment in pooled phase 2 and phase 3 baricitinib studies - Taylor PC, et al. Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study - Takeuchi T, et al. Effect of discontinuation or initiation of methotrexate or glucocorticoids on tofacitinib efficacy in patients with rheumatoid arthritis: a post-hoc analysis - Fleishmann R, et al. Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses - Strand V, et al. Effect of filgotinib, a selective JAK1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes - Genovese M, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial - Genovese MC, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial - Burmester GR, et al. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries - Choy E, et al. Two-year efficacy and safety of subcutaneous tocilizumab in combination with disease-modifying antirheumatic drugs including escalation to weekly dosing in rheumatoid arthritis - Kivitz A, et al. Patient characteristics influence the choice of biologic drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics - Frisell T, et al.